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measured at 0.5, 1, 3, 6 and 12 hours after the start of study drug. The primary end-
point was PCWP at 1 h. Adverse events were monitored through study day 3, and
mortality was assessed through a month.
Results: 93 patients were randomized to rhANP group and 28 to the placebo group at
a ratio of 3:1 using block of size 4. Baseline characteristics were similar among
patients in the study groups, and PCWP were 23.717.0 and 25.668.78 mmHg in
rhANP and placebo group, respectively (P¼0.226). The mean reduction in PCWP was
greater with rhANP (-5.45 mmHg) than placebo (-2.03 mmHg) at 30 minutes, and
there was signiﬁcant difference for the mean PCWP between groups (P¼0.002).
The maximum decrease of PCWP in rhANP group was observed at 1 h (-7.74 vs
-1.82 mmHg with placebo), and the mean PCWP of the two groups were signiﬁcantly
different (P<0.001). At 3 h, PWCP was sustainedly lower in rhANP group
(19.526.55 mmHg) than in placebo group (24.798.42 mmHg) (P<0.001). How-
ever, no signiﬁcant differences were found between the two groups for PCWP at
6 hours (21.436.51 and 24.7910.64 mmHg, P¼0.125). The rate of hypotension
and other adverse event were even in the two groups (P¼0.111).
Conclusions: The short-term infusion of rhANP has prompt hemodynamic
improvement in patients with congestive heart failure compared to placebo added to
standard care.
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Objectives: To investigate the effects of testosterone on heart function, cardiomyocyte
apoptosis, and ventricular remodeling in male rats post-myocardial infarction.
Methods: Eighty-six male rats were randomly assigned to undergo ligation of the
coronary artery (n¼70) or pseudo surgery (PS, n¼16). Six weeks later, a left ven-
tricular ejection fraction (LVEF) of 45% or less was deﬁned as a successful model of
CHF All model rats were randomly divided into 3 groups: low-dose testosterone (TU),
high-dose TU, and placebo (PL) group. After treatment for 12 weeks, the expression
of several mRNA transcripts in myocardial tissue was measured by real-time PCR.
Immunoﬂuorescence was used to measure myocardial caspase-3 expression.
Results: Compared with the PL group, TU treatment signiﬁcantly improved the
LVEF. Moreover, the mRNA expression of atrial natriuretic peptide (ANP), braim
natriuretic peptide (BNP), matrix metalloproteinase-2 (MMP-2), and sarco/endo-
plasmic reticulum Ca2+-ATPase 2a (SERCA2a) was signiﬁcantly reduced, while the
mRNA expression of glycogen synthase kinase 3b (GSK3b) and tissue inhibitor of
metalloproteinase-2 (TIMP-2) was markedly increased in the TU group. TU treatment
also signiﬁcantly reduced caspase-3 expression.
Conclusions: Different doses of testosterone suppressed ventricular remodeling and
improved left ventricular function, reduced apoptosis, and prevented mortality in a
CHF rat model.
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Objectives: Digoxin has been used for more than 200 years to treat patients with heart
failure (HF), however, there have been inconsistent ﬁndings on the association
between digoxin use and risk of death and heart failure hospitalization. Therefore, we
conduct a meta-analysis of cohort studies to assess the relationship between digoxin
use and the risk of death and heart failure hospitalization.
Methods:We searched the MEDLINE, Embase, CNKI (Chinese National Knowledge
Infrastructure) from January 1993 through October 2013 and reference lists of
retrieved articles, with the use of a standardized protocol which was registered in the
University of York Center for Reviews and Dissemination, the number is:
CRD42013006258. Two authors performed independent article review and study
quality assessment using the Newcastle-Ottawa Scale (NOS) checklist. A random-
effects model was used to calculate the overall combined risk estimates.
Results: Nine cohort studies involving 84, 692 participants were included in the meta-
analysis. The overall combined hazard risks with digoxin use compared with the
reference group were 1.149 (95% CI 1.043-1.266) for all-cause mortality, 1.059 (95%
CI 0.784-1.431) for heart failure hospitalization, 0.988 (95% CI 0.720-1.354) for all-
cause hospitalization. Sensitivity analysis of exclusion of any single study did not
materially alter the overall result. A little evidence of publication bias was observed.
Conclusions: This meta-analysis of cohort studies suggests that digoxin use signiﬁ-
cantly increases the risk of all-cause mortality, and has no effect on heart failure
hospitalization and all-cause hospitalization.
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Left atrial ejection force is independent of left atrial volume in heart failure
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University of Santo Tomas HospitalJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CObjectives: This study aimed at determining the correlation of left atrial ejection force
(LAEF) and left atrial volume in patients with heart failure.
Methods: This was a prospective cross sectional study done at the University of Santo
Tomas Hospital from October-December 2013. LAEF was computed using the
modiﬁed Manning’s Method. The left atrial volume was measured using the bi-plane
method. Correlation between the variables were analysed using the Pearson’s R.
Results: Thirty six patients were enrolled (22 males, 14 females). Mean age was
64.3613.23. The mean computed LAEF was increased at 16.611.6 kdynes. The
mean age corrected LAEF was increased at 287.83197 kdynes. Age and left atrial
volume were not signiﬁcantly correlated with computed LAEF and age corrected
LAEF (P value 0.121, 0.367, 0.187, 0.661). Only peak A velocity was found to be
signiﬁcantly correlated with computed (value 0.001) and age corrected LAEF (value
0.001).
Conclusions: LAEF was increased in patients with heart failure. Peak A velocity was
correlated with computed and age corrected LAEF. Hence, Peak A velocity maybe
used as a marker of overall left atrial function.
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Objectives: Heart failure (HF) is one of the global public health problems which have
important inﬂuence on human health. Red blood cell distribution width (RDW) is a
measure of the variability in the size of circulating erythrocytes. In recent years, more
and more studies have shown that RDW is a risk stratiﬁcation and powerful prognostic
indicator for patients with heart failure. In this study, we compared the RDW with the
already known heart failure marker to analysis the important value of RDW in heart
failure severity and prognosis.
Methods: We retrospectively investigated consecutive patients who visited the car-
diology department of China-Japan Union Hospital from January to June in 2013.
According to the inclusion and exclusion criteria, a total of 240 heart failure patients
were enrolled in the case group. There are each 80 patients in the NYHA II, NYHA III
and NYHA IV group. We selected 200 patients without heart failure as the control
group.For each patient, detailed records of the patient’s information. And fasting
blood taken after admission of all enrolled patients to measured serum creatinine,
blood urea nitrogen, brain natriuretic peptide, and left ventricular ejection fraction
(LVEF) was measured with echocardiography.
Results: Compared with the control group, RDW level was signiﬁcantly higher in the
heart failure group (P<0.001). The RDW level was increased as the NYHA classi-
ﬁcation grade. There is a correlation between RDW and LVEF as well as log
[NT-proBNP], the RDW was signiﬁcantly positive correlated with LVEF (r¼-0.481,
P<0.05) and negative correlated with log[NT-proBNP] (r¼0.0637, P<0.001). The
RDW level, LVEF, eGFR and log [NT-proBNP] was signiﬁcantly different between
the cardiovascular events group and non-events group, and the COX regression
analysis showed that RDW and Log [NT-BNP] are independent factors affecting the
cardiovascular events. ROC analysis showed that there is no signiﬁcant different
between the RDW and Log [NT-proBNP] when using the Z test to measure the area
under the curve (P>0.05). While when using the Kaplan-Meier survival curve anal-
ysis, select RDW13.85% as cutoff to compare for the survival time of readmission, the
incidence of cardiovascular events. Signiﬁcant differences was found between all
these groups (P<0.001); RDW quartile grouped by comparing survival time increased
with RDW, gradually shortened survival time, a signiﬁcant difference (P<0.001)
between the survival curves.
When using quartile grouped methods to compare the cardiovascular events in each
group, we found that at the Q2 stage the RDW is more effective to predict all the
cardiovascular events compared with log [NT-proBNP].
Conclusions: RDW is signiﬁcantly higher in patients with heart failure, and is
signiﬁcantly elevated with NYHA class severity. RDW is negatively correlated with
LVEF, and is positively correlated with log [NT-proBNP]. Therefore, RDW may act
as an important indicator to determine the severity of the patient and as a powerful
prognostic marker to evaluate the cardiovascular events in heart failure patients.
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Objectives: To explore the effect of levosimendan on patients with decompensated
heart failure (DHF) and summarize the key points of nursing.
Methods: Eighty-six patients with DHF were randomly divided into levosimendan
group (n¼43) and control group (n¼43). Patients in control group received the
conventional treatment including diuretics, ACE inhibitors, beta-blockers, aldosterone
antagonists and digitalis, while patients in levosimendan group received an extra
intravenous administration of levosimendan for 24 hours. Echocardiography, level of
amino-terminal pro-brain natriuretic peptide (NT-pro BNP), blood pressure (BP),
heart rate (HR) and blood electrolytes were detected and compared. The changes of
symptoms including dyspnea and leg swelling, and adverse events were recorded.
Results: Compared with control group, there were a signiﬁcant increase in SV
[(62.7223.21) ml vs (71.1223.76) ml] and a signiﬁcant decrease in NT-pro BNPardiovascular Disease Clinical Research C183
